Next Article in Journal
Role of Mitochondria in Environmentally and Dietary Modulated Age-Associated Diseases
Previous Article in Journal
Interstitial Macrophages Lead Early Stages of Bleomycin-Induced Lung Fibrosis and Induce Fibroblasts Activation
Previous Article in Special Issue
GABAA and GABAB Receptors Mediate GABA-Induced Intracellular Ca2+ Signals in Human Brain Microvascular Endothelial Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 12
Issue 3
10.3390/cells12030403
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Calnexin, More Than Just a Molecular Chaperone

by
Tautvydas Paskevicius
1,
Rabih Abou Farraj
1,
Marek Michalak
1,* and
Luis B. Agellon
2,*
1
Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2R3, Canada
2
School of Human Nutrition, McGill University, Sainte Anne de Bellevue, QC H9X 3V9, Canada
*
Authors to whom correspondence should be addressed.
Cells 2023, 12(3), 403; https://doi.org/10.3390/cells12030403
Submission received: 4 January 2023 / Revised: 17 January 2023 / Accepted: 17 January 2023 / Published: 24 January 2023
(This article belongs to the Special Issue Cell Calcium across the Phylogenetic Tree: From Physiological Signaling to Pathogenic Mechanisms)
Browse Figures
Versions Notes

Abstract

:
Calnexin is a type I integral endoplasmic reticulum (ER) membrane protein with an N-terminal domain that resides in the lumen of the ER and a C-terminal domain that extends into the cytosol. Calnexin is commonly referred to as a molecular chaperone involved in the folding and quality control of membrane-associated and secreted proteins, a function that is attributed to its ER- localized domain with a structure that bears a strong resemblance to another luminal ER chaperone and Ca2+-binding protein known as calreticulin. Studies have discovered that the cytosolic C-terminal domain of calnexin undergoes distinct post-translational modifications and interacts with a variety of proteins. Here, we discuss recent findings and hypothesize that the post-translational modifications of the calnexin C-terminal domain and its interaction with specific cytosolic proteins play a role in coordinating ER functions with events taking place in the cytosol and other cellular compartments.

1. Introduction

The endoplasmic reticulum (ER) is organized as a continuous membrane network of branching tubules and flattened sacs that envelop a single lumen. The ER performs a plethora of functions in cells, including lipid and steroid synthesis, Ca2+ storage and signaling, protein synthesis and maturation involving protein folding and post-translational modification [1,2,3]. Human cells express approximately 10,000 different proteins at any given moment [4]. More than a third of all of these proteins are synthesized on ER membrane-bound ribosomes where proteins are either destined for residence in the ER, plasma membrane, Golgi apparatus, lysosomes or secreted from the cell [5]. Even though the native structure and conformation of a given protein is largely determined by its amino acid sequence [6], many newly synthesized proteins require assistance by molecular chaperones to reach their native fold at a biologically relevant time scale [7]. To help facilitate proper folding and quality control, the ER employs two major folding systems: the general pathway that is mediated by BiP (the ER homolog of the 70-kDa heat shock protein, Hsp70) together with protein disulfide isomerase PDIA1, and the N-linked glycoprotein pathway which is governed by lectin chaperones calnexin and calreticulin, commonly referred to as the calnexin/calreticulin cycle [8]. Both calreticulin and calnexin share structural similarity with respect to their lectin-like domains with calreticulin being an ER lumen-resident protein while calnexin is a type I integral ER membrane protein with a transmembrane helix and cytosol-exposed C-terminal domain. This review is focused on the role of calnexin not only as an ER chaperone involved in the protein quality control pathway but also on the emerging view on its importance in coordinating ER and cytosolic events via the unique interactions of calnexin with a variety of proteins at the ER–cytosol interface [9,10,11,12,13,14].

2. Discovery of Calnexin

In 1982 a novel ER-associated protein with an apparent mass of 90 kDa was detected using polyclonal antiserum raised against membrane fractions of rough ER [15]. Cell culture immunofluorescence analysis using these anti-rough ER antibodies revealed an extensive, reticular network of membrane occupying the entire cytoplasm and extending to the nuclear membrane [15]. However, it was not until a decade later when the 90 kDa phosphoprotein (referred to as pp90) was identified as being associated with ER signal sequence receptor complexes in canine pancreatic microsomes [16]. Two other research groups simultaneously reported the identification of p88 (reported as an 88 kDa protein) in transient association with partially assembled class I major histocompatibility molecules in murine lymphoma cell lines [17] and IP90 (reported as a 90 kDa intracellular protein) interacting with T-cell antigen and B-cell antigen receptor complexes [18]. Molecular cloning and characterization of the canine IP90 cDNA revealed that its encoded protein was a type I ER membrane protein [16]. Due to its Ca2+-binding properties [16] and a high degree of amino acid sequence similarity with calreticulin [19], a major Ca2+-binding ER resident protein, the pp90 protein was named calnexin [16,20,21,22]. Since then, calnexin has been observed to interact transiently with a wide array of nascent membrane or soluble N-linked glycoproteins.
Calnexin, together with calreticulin and ERp57 (also known as PDIA3) [23], forms the core components of a pathway that facilitates the folding and quality control of newly synthesized proteins with N-linked carbohydrate side chains [24,25]. This folding pathway has been widely studied and therefore well characterized and described in several excellent review articles [26,27,28,29,30,31]. Today it is well established that calnexin is ubiquitously expressed in all cells containing the ER membrane. It is highly conserved among different species (Figure 1), with its intraluminal domain responsible for chaperone function displaying the highest level of conservation and indicating the evolutionary importance of the chaperone domain of calnexin. Calnexin can be found distributed within different ER membrane subdomains, including a variety of ER membrane contact sites [32] such as perinuclear rough ER contacts with the ribosome–translocon complex [33,34], smooth ER, nuclear envelope and the mitochondria/ER contact sites (also referred to as the mitochondria-associated membrane [12,35]. The characteristic distribution of calnexin molecules within ER membranes is controlled by the post-translational modifications including palmitoylation and phosphorylation at its C-terminal domain, which are discussed later. Moreover, it was initially reported that calnexin is present on the cell surface of immature thymocytes in a complex with the CD3 antigen due to incomplete ER retention [36,37]. Other studies have detected small amounts of calnexin on the cell surface of various cell types [38]; the redistribution of calnexin between ER and plasma membranes was proposed to be controlled by the state of calnexin C-terminal domain phosphorylation and association with phosphofurin acidic cluster sorting protein 2 (PACS-2) [39]. Moreover, plasma membrane localization of calnexin has been detected in cancerous tumors such as oral squamous cell carcinoma and melanoma [40] while another study reported calnexin as being secreted in the serum of lung cancer patients, making calnexin a possible sero-diagnostic marker [41].

2.1. Calnexin-Deficient Animal Models

Much of the early work on calnexin focused on biochemical and cellular aspects. Thus, animal models lacking calnexin were created to gain insight into its physiological importance. D. melanogaster has three genes encoding calnexin among which calnexin99A has the highest similarity with mammalian calnexin [44]. Mutations in calnexin99A affected the maturation and function of rhodopsin, which in turn led to age-dependent retinal degeneration [44]. Additionally, calnexin99A mutants displayed impaired Ca2+ buffering, which contributed to the development of the retinal degeneration possibly due to Ca2+ toxicity [44]. Inactivation of the calnexin gene in C. elegans resulted in developmental and reproductive defects that were temperature sensitive [45]. These mutant worms also exhibited growth impairment under calcium insufficiency [45]. Furthermore, RNAi-mediated silencing of the calnexin gene resulted in suppressed necrotic-like cell death [46]. In D. rerio (zebrafish), calnexin is required for the development of the mechanosensory system called the lateral line [47]. Upon the knockdown of calnexin, zebrafish exhibited reduced posterior lateral line cell proliferation and increased ER stress-dependent apoptosis [47].
Two independent calnexin-deficient mouse strains have been generated [48,49]. Unlike calreticulin deficiency which is embryonic lethal due to impaired Ca2+-dependent transcriptional regulation resulting in defective cardiac development [50], calnexin-deficient mice were born live but exhibited a high degree of neonatal lethality [48,49]. Calnexin-deficient mice were born with neurological disorders that included severe ataxia [48,49]; however, one functional calnexin allele is sufficient to prevent this defect [48]. The first study described the high early postnatal mortality of calnexin-deficient mice [49] and surviving mice exhibited ataxia due to the substantial loss of motor nerve fibers. The subsequent study by Kraus et al. [48] found however that surviving calnexin-deficient mice were fertile, had a normal life span, but were 30–50% smaller than their wild-type littermates. These mice developed peripheral neuropathy abnormalities manifesting as gait disturbance with instability, splaying of the hind limbs, tremors and a rolling walk but no reduction in the numbers of neuronal fibers was apparent [48]. Additionally, another mouse strain expressing a mutant form of calnexin-lacking amino acid residues 103–242 (encoded by exons 4–6), which deleted the regions involved in disulfide bond formation (Cys141 and Cys175) and carbohydrate binding (Tyr145 and Lys147), exhibited features that were identical to the calnexin-deficient mice, suggesting that the loss of chaperone function was responsible for the observed neurological defect [48,49]. Consistent with this idea, mice that only express the truncated version of calnexin lacking the C-terminal domain do not have apparent disturbances in motor function and display normal motor and sensory nerve conduction velocities [51]. Surprisingly, calnexin-deficient mice display no apparent aberrations in immune system development and function [48].
It is interesting to note that despite the ubiquitous presence of calnexin in all cells that possess an ER network, the loss of calnexin in the whole organism does not produce a common phenotype but rather manifests in a variety of phenotypes.

2.2. Calnexin as a Molecular Chaperone

It is predicted that more than 30% of all eukaryotic proteins are glycoproteins with more than 90% of these containing N-linked sugars [52]. The folding and maturation of newly synthesized glycoproteins in the ER is assisted by calnexin and its soluble ER lumen-resident homolog, calreticulin. Whereas calnexin binds to glycans in protein domains that are close to membranes, calreticulin interacts with glycans that extend deeper into the ER lumen [31]. Immediately after the nascent polypeptide exits the translocon and enters the ER lumen, oligosaccharyltransferase transfers dolichol-pyrophosphate-bound branched core glycan to the sidechain nitrogen of the asparagine residue of the N-glycosylation consensus sequence motif (Asn-X-Ser/Thr, where X is any amino acid except for proline) [53]. The branched core oligosaccharide is comprised of three terminal glucoses, nine mannoses, and two N-acetyl-glucosamines (Glc3Man9GlcNAc2). After the glycosylation, N-linked glycans are then processed by the subsequent action of endoplasmic reticulum (ER) glucosidases I (GI) and II (GII) removing the outer and middle glucose residues, respectively. As a result, the processing intermediate containing the single terminal glucose moiety is specifically recognized by calnexin and calreticulin [24,54,55]. Additionally, using their extended arm-like P-domains, calnexin and calreticulin recruit ERp57, cyclophilin B and ERp29 (also known as PDIA9) [56,57,58,59,60] to promote glycoprotein folding and maturation. Subsequently, the remaining innermost glucose moiety is removed by GII releasing the glycoprotein substrate from the calnexin–calreticulin complex. If the protein is correctly folded at this point, it is released from the ER and transferred to the Golgi apparatus to continue its journey along the secretory pathway. However, if the protein has not reached its native three dimensional conformation, it is re-glucosylated by the ER-folding sensor uridine diphosphate (UDP)-glucose:glycoprotein glucosyl transferase (UGGT) facilitating the re-association with calnexin and calreticulin for an additional round of the folding cycle [61]. Thus, the protein can re-enter the calnexin/calreticulin cycle multiple times until the native conformation is reached.
If numerous folding cycles fail to properly fold the protein, the misfolded protein is marked for degradation. Terminally misfolded glycoproteins and unassembled oligomers are retro-translocated to the cytosol and are degraded by the ubiquitin-proteasome system, a process known as ER-associated degradation (ERAD) [62]. This process is regulated by ER α-mannosidase I [63] and ER degradation-enhancing α-mannosidase-like protein (EDEM) [64]. Proteins undergoing multiple calnexin/calreticulin cycles are eventually subjected to mannose trimming by ER α-mannosidase I converting Man9GlcNAc2-glycans to Man8GlcNAc2 [65]. The slow kinetics of this enzyme essentially act as a timer for repeated glycoprotein folding cycles [66]. As a result, Man8GlcNAc2 becomes less efficient UGGT substrate [27] and instead is recognized by EDEM which acts as a signal triggering ERAD [67]. EDEM directly interacts with calnexin and accepts terminally misfolded glycoproteins upon mannose trimming [68,69]. This is followed by retro-translocation into the cytosol where the misfolded proteins are polyubiquitinated which are then degraded by the cytosolic 26S proteasome [70].
In the event of persistent ER stress and the extensive accumulation and aggregation of misfolded proteins, a selective form of autophagy named ER-phagy is used to ensure the timely removal of damaged ER [71]. During this process excessive or damaged portions of ER are fragmented and sequestered through ER-phagy receptors by double-membrane autophagic vesicles that eventually fuse with lysosomes for degradation [71]. It has been shown that calnexin makes a stable complex with the ER-phagy receptor FAM134B [72]. In collagen-producing cells calnexin acts as a co-receptor recognizing misfolded procollagen molecules in the ER lumen triggering FAM134B to recruit and bind the autophagosome membrane-associated protein LC3. In turn, this ER-phagy complex delivers a targeted portion of ER that contains both misfolded procollagen and calnexin to the lysosome for degradation [72]. Additionally, it has been shown that calnexin-FAM134B can facilitate the clearance of proteasome-resistant polymers of α1-antitrypsin Z in ER through a different vesicular transport pathway [73]. This pathway is known as the ER-to-lysosome-associated degradation (ERLAD), since ER-derived vesicles containing misfolded proteins are not encapsulated by autophagosomes but instead fuse with endosomes for degradation [73].
It was initially proposed that calnexin was an important factor in the development of the immune system, considering its importance in the folding and quality control of secreted and membrane-bound glycoproteins. It has been suggested that calnexin is involved in the folding and assembly of major histocompatibility complex (MHC) class I, although one study using a cultured cell model showed that these proteins can fold properly in the absence of calnexin [74,75,76,77,78,79,80]. Additionally, calnexin participates in MHC class II [81], T-cell antigen receptor (TCR) [21,82,83,84,85] and B-cell antigen receptor (BCR) [86,87,88] assembly and maturation. However, since mice with whole-body calnexin deficiency display normal immune function, it is apparent that calnexin is not essential for the development of the immune system in this species [48].

3. Structure of Calnexin

The gene for human calnexin (CANX) is located towards the distal end of the long arm of chromosome 5 (5q35.3 locus) spanning ~33 kbp and comprised of 15 exons [89] (Figure 2). It makes a mature transcript of 4915 bp that is translated into a 592 amino acid residue polypeptide.
Meanwhile, the mouse calnexin gene (Canx) is located on a reverse strand of the long arm of murine chromosome 11 and has a similar arrangement but with only 14 exons that are transcribed into a 4281 bp transcript which encodes a polypeptide of 591 amino acid residues. The human calnexin polypeptide is a 67 kDa type-I integral membrane protein but is often mistakenly referred to as a 90 kDa protein due to its high content of acidic residues which electrostatically repel SDS resulting in an insufficient electromotive incentive and a lowered electrophoretic mobility on SDS-PAGE. The calnexin polypeptide is composed of three topological domains (Figure 2 and Figure 3): an N-terminal ER intraluminal domain, a transmembrane segment and a cytosol-facing C-terminal domain [16]. The ER luminal domain is responsible for chaperone function and thus is often referred to as the folding module [56,90]. The transmembrane segment anchors calnexin to the ER membrane and possibly also contributes to its chaperone function [91]. Finally, the 90 amino acid long C-terminal domain is oriented towards the cytosol and undergoes several distinct post-translational modifications [12,33,35,92,93,94,95,96,97].

3.1. The ER Lumen-Localized N-Terminal Domain

The ER luminal domain of calnexin is responsible for its lectin-like chaperone function and is the site for interaction with cyclophilin B, ERp29 and ERp57 [56,57,58,59,60]. It also contains a 20 amino acid residue N-terminal signal sequence that is responsible for targeting calnexin into the ER. The crystal structure of the intraluminal portion of canine calnexin was solved by Schrag et al. [99] at 2.9 Å resolution and revealed the asymmetry featuring two distinct structural components comprised of a compact globular domain towards the N-terminus (referred to as the N-domain) and an elongated arm-like proline-rich domain (referred to as the P-domain) towards the C-terminus (Figure 4) [99]. The N-domain is composed of concave and convex antiparallel β sheets that have six and seven β strands, respectively, which together form a β-sandwich structure [99]. The calnexin luminal domain co-crystallized with α-D-glucose revealed the site for the carbohydrate binding within N-domain on the concave β sheet, where Tyr144, Lys146, Tyr165, Glu196 and Glu405 (coordinates refer to the human calnexin amino acid sequence) form hydrogen bonds with glucose hydroxyl groups, while the Met168 sidechain interacts with the glucose ring via van der Waals interactions [99].
The P-domain [100] extends 140 Å away from the N- domain and forms a large hairpin loop (Figure 4). This loop consists of two types of motifs (Motif 1 and Motif 2) of proline-rich sequence repeats bearing the consensus sequence of I-DP(D/E)A-KPEDWD(D/E) and G-W-P-IN-P-Y, respectively. Each motif is repeated four times and arranged in a linear manner ‘11112222’ where four repeats of motif 1 extend away from the N-globular domain and then fold back onto the strand with four repeats of motif 2. Every copy of motif 1 interacts with a copy of motif 2 in a head-to-tail fashion [99]. This hook-like arm is further stabilized via hydrophobic interactions of conserved isoleucine residues [26]. In addition, there are three regions of high amino acid sequence similarity, flanking the repeat motifs. Both N-globular and P-domain harbors one disulfide bond: Cys140–Cys174 and Cys340–Cys346, respectively, in the human calnexin sequence [99].
Early studies indicated that calnexin harbous multiple low affinity Ca2+ binding sites in both the N- and C-terminal regions [16,89]. However, the three-dimensional structure of the luminal domain revealed only a single putative Ca2+ binding site coordinated by Asp416, Asp97 and Ser54 [99]. This Ca2+ binding site is highly conserved between calnexin and calreticulin, as the P-domain of calreticulin also binds a single Ca2+ ion with high affinity [101] through Asp328 (refers to human calreticulin; homologous to Asp416 in calnexin), Gln26, Lys62, and Lys64, with two water molecules [99]. Moreover, the binding of Ca2+ to the ER luminal portion of calnexin plays a structural role by triggering Ca2+-dependent conformational changes [102]. In addition, the calnexin luminal domain was shown to bind Zn2+ and ATP; both regulate conformational changes [102], while ATP alone enhances the aggregation suppression abilities in vitro, even though no ATPase activity has been reported [103], and Zn2+ facilitates the binding of ERp57 [104].

3.2. The Transmembrane Domain

Using a molecular dynamics simulation, a single transmembrane spanning domain comprised on an α-helix was predicted for calnexin. The Pro494 (refers to the human calnexin sequence) at approximately the midpoint of the α-helix introduces a tilt of ~30° with respect to the surface of the membrane (Figure 3) [34]. Replacement of the Pro494 with leucine to remove the kink in the transmembrane helix negatively affects the interaction between calnexin and the ribosome–translocon complex [34]. It was proposed that the anchoring of calnexin to the ER membrane facilitates its association with membrane-bound substrates, enhancing its chaperone function [91].

3.3. The Cytosolic C-Terminal Domain

Much of the work characterizing the function of calnexin has focused on the intraluminal and transmembrane domain and consequently little is known about the C-terminal domain. It is known that the C-terminal domain plays an important role in the retention of calnexin in the ER as this domain contains the RKPRRE motif, which acts as an ER retention sequence [105]. To date, no structural information about the calnexin C-terminal domain is available. This highly acidic 90 amino acid long segment (theoretical pI of 4.52 for human calnexin) faces the cytosol and is thought to be flexible and unstructured [16,26]. The acidic nature of this domain contributes to the unusual electrophoretic mobility of the calnexin in SDS-PAGE. Based on the number of amino acids encoded by the calnexin mRNA, the predicted molecular mass of calnexin is 67 kDa. However, the apparent molecular mass of calnexin on SDS-PAGE gels is dramatically increased to 90 kDa protein. The anionic character of the calnexin C-terminal domain imparts this domain with multiple low affinity, but high capacity Ca2+-binding sites [87].

4. Post-Translational Modifications of the Calnexin C-Terminal Domain

Unlike the compact luminal domain of calnexin, the cytosol-exposed C-terminal domain appears to be unstructured which makes it easily accessible. Indeed, recent studies have found that the cytosol-exposed C-terminal domain undergoes post-translational modifications, which include palmitoylation [92,93,94], phosphorylation, sumoylation [12,33,35,95,96,97] and proteolytic cleavage [10] (Figure 3).

4.1. Palmitoylation

Calnexin is palmitoylated at both juxtamembranous cysteines Cys502 and Cys503 (or Cys482 and Cys483 counting from the mature N-terminus) by an ER palmitoyltransferase DHHC6 [34]. Over 90% of calnexin molecules are S-acylated at a steady state suggesting that the cell maintains constant pamitoylation-depalmitoylation cycles of calnexin [34]. Moreover, molecular dynamics simulations predicted that upon palmitoylation, the C-terminal domain adopts different conformations with respect to the transmembrane helix axis suggesting that palmitoylation might affect the capacity and/or selectivity of calnexin to interact with additional proteins outside the ER via its cytosolic C-terminal domain. Palmitoylation at Cys503 was predicted to have a more prominent effect on the conformation of the C-terminal domain, suggesting possible functional/regulatory difference between Cys502 and Cys503 state of palmitoylation. Using both computational and experimental approaches, it has been shown that the calnexin half-life increases 9-fold upon palmitoylation [106]. As a functional consequence, the palmitoylation of both cysteines preferentially localizes calnexin to the perinuclear rough ER while also facilitating the association with the ribosome–translocon complex. This association was shown to be crucial for chaperone function, as calnexin can capture its substrates as they emerge through translocon [34]. Other studies have also shown that palmitoylated calnexin is localized to the mitochondria-ER contact sites [107,108], where it interacts and controls sarco-endoplasmic reticulum Ca2+ transport ATPase 2b (SERCA2b) [13], an interaction that modulates ER-mitochondria Ca2+ signaling [11,12,35]. It has been shown that upon short-term ER stress, the pool of palmitoylated calnexin is reduced, shifting non-palmitoylated calnexin localization to rough ER where it interacts with ERp57 to facilitate protein folding and quality control [12]. Further studies should help to clarify the impact of calnexin redistribution on the remodeling of cellular processes and the regulation of cellular function.

4.2. Phosphorylation

Calnexin harbors three phosphorylation sites in its C-terminal domain: Ser534, Ser544 and Ser563 (in the human calnexin sequence). These sites are known to be phosphorylated by casein kinase CK2 (at Ser534 and Ser544) [97,109] and extracellular signal-regulated kinase-1 ERK-1 (at Ser563) [33]. ERK-1 is activated by mitogen-activated protein kinase 1 MEK1 under conditions that promote protein misfolding [110]; therefore, the phosphorylation state of Ser563 exemplifies calnexin function in ER quality control. Upon ER stress, detection of misfolded protein accumulation leads to ERK-1 activation and enhanced calnexin phosphorylation at Ser563 which in turn leads to the specific recruitment of calnexin to ER-membrane bound ribosomes. This specific recruitment facilitates calnexin function as a chaperone to enhance glycoprotein quality control at the ER ribosome–translocon complex by prolonging its association with unfolded proteins [33,95]. In synergy with the phosphorylation of Ser563, the phosphorylation of Ser534 and Ser544 by CK2 further promotes calnexin–ribosome interaction [33]. Moreover, the phosphorylation of these two residues disrupts calnexin interaction with phosphofurin acidic cluster sorting protein 2 (PACS-2), a key regulator of mitochondria/ER contact sites [111], thus shifting calnexin distribution from these sites to rough ER [39]. Another study also showed that calcineurin, a Ca2+-dependent phosphatase, dephosphorylates Ser563 [112] thereby controlling the phosphorylation status of Ser563 which was shown to also modulate calnexin interaction with SERCA2b which in turn regulate intracellular Ca2+ oscillations [13]. Taken together, phosphorylation of calnexin in its C-terminal domain illustrates another level of complexity in controlling calnexin distribution among different ER membrane subdomains and therefore influences its function.

4.3. SUMOylation

Sumoylation is a type of post-translational modification involving the covalent attachment of the small ubiquitin-related modifier (SUMO) protein (∼10 kDa) to certain proteins [113]. Calnexin interacts with sumoylation E2 ligase UBC9 via its C-terminal domain and undergoes sumoylation at Lys505 [96]. Sumoylated calnexin interacts with protein tyrosine phosphatase 1B PTP1B [96], linking the protein quality control pathway with insulin and leptin signaling [114].

4.4. Proteolytic Cleavage

It was previously reported that apoptotic stimuli caused calnexin to undergo proteolytic cleavage at its C-terminal domain by either caspase-3 or caspase-4 at a DXXD site resulting in the attenuation of apoptosis [9]. Another study showed that cells stimulated with epidermal growth factor (EGF) triggers caspase-8-dependent proteolytic cleavage of the calnexin C-terminal domain at Asp519 yielding a 63 amino acid peptide [10] that translocates to the nucleus where it makes a stable complex with Protein Inhibitor of Activated STAT 3 (PIAS3) thus preventing PIAS3 from inhibiting Signal Transducer and Activator of Transcription 3 (STAT3). Palmitoylation of calnexin, which targets it to mitochondria/ER contact sites, is required for EGF-induced cleavage of calnexin whereas ER stress prevents its proteolytic cleavage [10].
 
Despite some variation in the calnexin C-terminal primary structure (Figure S1), the positions of Cys502, Cys503, Ser563, Ser534, Ser544, Lys505, which represent sites for post-translational modifications (Figure 3), are moderately conserved (ranging from 44 to 65%) suggesting similar modifications might also occur in different organisms.

5. The Calnexin C-Terminal Domain, a Cytosol-ER Regulatory Nexus

In addition to modifying enzymes, recent studies have found that the C-terminal domain of calnexin interacts with a variety of proteins [14,96,115,116,117,118] which, depending on the type of modifications introduced, have a substantial impact on cellular homeostasis and function. Some of the cellular processes affected by the post-translational modification of the C-terminal domain have already been described in the preceding section.
Endocytosis is an example of a cellular process that is altered via the calnexin C-terminal domain. It has been found that the binding of SGIP1 to the calnexin C-terminal domain inhibits clathrin-dependent endocytosis in neuronal cells, and the absence of calnexin in mice causes an increased endocytosis in the nervous system [15]. Cellular efflux of substrate cholesterol is similarly altered via the calnexin C-terminal domain. The binding of the human immunodeficiency virus (HIV) protein Nef to ABCA1, the main cellular cholesterol transporter, disrupts the interaction of calnexin with ABCA1, leading to its retention in the ER and eventual degradation, thereby inhibiting ABCA1-dependent cholesterol efflux [119]. The accumulation of HIV-infected cells accumulate cholesterol in HIV infected cells leads to the increased formation of plasma membrane lipid rafts which serve as sites of HIV entry, assembly, and budding [120]. Moreover, Nef promotes the interaction calnexin with the HIV glycoprotein protein gp160 enhancing HIV envelope protein maturation [119].
Further insight into the pathophysiological relevance of the calnexin C-terminal domain was provided by recent studies on a complex formed by the calnexin C-terminal domain and the cytosolic protein Fabp5 (also referred to as epidermal fatty acid binding protein). This unexpected complex was detected during a search for calnexin interaction partners using the yeast two-hybrid system [118]. While whole-body calnexin deficiency leads to myelinopathy in mice [48], loss of calnexin also causes resistance to induction of experimental autoimmune encephalomyelitis (EAE), a model of inflammatory central nervous system demyelination, coincident with the phenotype of whole-body Fabp5 deficiency [121,122]. In fact, deletion of the calnexin cytosolic C-terminal domain, the site for Fabp5 interaction, is sufficient to impart resistance to EAE induction [51]. This resistance due to the inhibition of circulating T-cell infiltration across endothelial cells of the blood–brain barrier when the formation of the complex between calnexin C-terminal domain and Fabp5 was prevented [51,121]. In contrast, experiments using a cell culture model of the blood–brain barrier demonstrated that promoting the formation of the calnexin/Fabp5 complex enabled T-cells to traverse the endothelial cells of the blood–brain barrier model [51]. It is possible that the stable interaction of Fabp5 with the calnexin C-terminal domain prevents calnexin from interacting with other regulatory proteins or from redistributing to subdomains of the ER membrane system.
The ability of the calnexin C-terminal domain to undergo distinct post-translational modifications and interact with regulatory proteins suggests that the calnexin C-terminal domain is a dynamically modifiable segment of a key ER-resident protein that acts as an interface for facilitating communication between cytosolic and ER processes.

6. Summary

Calnexin was first characterized as a molecular chaperone in the ER. The structure of calnexin resembles calreticulin, another ER-resident chaperone and Ca2+-binding protein. Calnexin and calreticulin, along with additional accessory ER proteins that include ERp57, participate in the calnexin/calreticulin cycle responsible for the folding and maturation of glycosylated proteins synthesized in the ER some of which are destined for cellular export. Unlike calreticulin however, calnexin is anchored to the ER membrane via its transmembrane domain and its C-terminal domain that extends to the cytosol. Recent studies have discovered that the calnexin C-terminal domain is subject to post-translational modification featuring lipidation, sumoylation, phosphorylation and proteolytic cleavage. These modifications result in the redistribution of calnexin within ER membranes and are associated with the remodelling of cellular processes. Other cytosolic proteins have also been found to interact with the calnexin C-terminal domain and influence cellular function, indicating that these interactions are important in integrating cytosolic and ER events. These findings help pave the way towards the identification and characterization of new calnexin functions, in addition to its well-recognized role as a molecular chaperone.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells12030403/s1, Figure S1: Amino acid sequence alignment of calnexin from multiple species.

Author Contributions

Conceptualization, T.P., M.M., L.B.A.; writing—original draft preparation, T.P.; Computer modeling, T.P., R.A.F.; writing—review and editing, T.P., R.A.F., M.M., L.B.A.; funding acquisition, M.M., L.B.A. All authors have read and agreed to the published version of the manuscript.

Funding

Our research is supported by grants from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada in our laboratories (to L.B.A. and to M.M.), and a generous donation from the Kenneth and Sheelagh McCourt family and University Hospital Foundation to M.M.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new experimental data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments

T.P. was a recipient of an endMS Personnel Award from the Multiple Sclerosis Society of Canada and by a Women and Children’s Health Research Institute Studentship Award.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Fagone, P.; Jackowski, S. Membrane phospholipid synthesis and endoplasmic reticulum function. J. Lipid Res. 2009, 50, S311–S316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Braakman, I.; Hebert, D.N. Protein folding in the endoplasmic reticulum. Cold Spring Harb. Perspect. Biol. 2013, 5, a013201. [Google Scholar] [CrossRef] [Green Version]
  3. Clapham, D.E. Calcium signaling. Cell 2007, 131, 1047–1058. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Kulak, N.A.; Geyer, P.E.; Mann, M. Loss-less Nano-fractionator for High Sensitivity, High Coverage Proteomics. Mol. Cell Proteom. 2017, 16, 694–705. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Anelli, T.; Sitia, R. Protein quality control in the early secretory pathway. EMBO J. 2008, 27, 315–327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Anfinsen, C.B. Principles that govern the folding of protein chains. Science 1973, 181, 223–230. [Google Scholar] [CrossRef] [Green Version]
  7. Balchin, D.; Hayer-Hartl, M.; Hartl, F.U. In vivo aspects of protein folding and quality control. Science 2016, 353, aac4354. [Google Scholar] [CrossRef] [PubMed]
  8. Ellgaard, L.; McCaul, N.; Chatsisvili, A.; Braakman, I. Co- and Post-Translational Protein Folding in the ER. Traffic 2016, 17, 615–638. [Google Scholar] [CrossRef] [Green Version]
  9. Takizawa, T.; Tatematsu, C.; Watanabe, K.; Kato, K.; Nakanishi, Y. Cleavage of calnexin caused by apoptotic stimuli: Implica-tion for the regulation of apoptosis. J. Biochem. 2004, 136, 399–405. [Google Scholar] [CrossRef]
  10. Lakkaraju, A.K.; van der Goot, F.G. Calnexin controls the STAT3-mediated transcriptional response to EGF. Mol. Cell 2013, 51, 386–396. [Google Scholar] [CrossRef]
  11. Gutiérrez, T.; Qi, H.; Yap, M.C.; Tahbaz, N.; Milburn, L.A.; Lucchinetti, E.; Lou, P.H.; Zaugg, M.; LaPointe, P.G.; Mercier, P.; et al. The ER chaperone calnexin controls mitochondrial positioning and respiration. Sci. Signal. 2020, 13, eaax6660. [Google Scholar] [CrossRef] [PubMed]
  12. Lynes, E.M.; Raturi, A.; Shenkman, M.; Ortiz Sandoval, C.; Yap, M.C.; Wu, J.; Janowicz, A.; Myhill, N.; Benson, M.D.; Camp-bell, R.E.; et al. Palmitoylation is the switch that assigns calnexin to quality control or ER Ca2+ signaling. J. Cell Sci. 2013, 126, 3893–3903. [Google Scholar] [CrossRef] [Green Version]
  13. Roderick, H.L.; Lechleiter, J.D.; Camacho, P. Cytosolic phosphorylation of calnexin controls intracellular Ca2+ oscillations via an interaction with SERCA2b. J. Cell Biol. 2000, 149, 1235–1248. [Google Scholar] [CrossRef] [Green Version]
  14. Li, H.D.; Liu, W.X.; Michalak, M. Enhanced clathrin-dependent endocytosis in the absence of calnexin. PLoS ONE 2011, 6, e21678. [Google Scholar] [CrossRef] [Green Version]
  15. Louvard, D.; Reggio, H.; Warren, G. Antibodies to the Golgi complex and the rough endoplasmic reticulum. J. Cell Biol. 1982, 92, 92–107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Wada, I.; Rindress, D.; Cameron, P.H.; Ou, W.J.; Doherty, J.J., 2nd; Louvard, D.; Bell, A.W.; Dignard, D.; Thomas, D.Y.; Ber-geron, J.J. SSR alpha and associated calnexin are major calcium binding proteins of the endoplasmic reticulum membrane. J. Biol. Chem. 1991, 266, 19599–19610. [Google Scholar] [CrossRef] [PubMed]
  17. Degen, E.; Williams, D.B. Participation of a novel 88-kD protein in the biogenesis of murine class I histocompatibility mole-cules. J. Cell Biol. 1991, 112, 1099–1115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Hochstenbach, F.; David, V.; Watkins, S.; Brenner, M.B. Endoplasmic reticulum resident protein of 90 kilodaltons associates with the T- and B-cell antigen receptors and major histocompatibility complex antigens during their assembly. Proc. Natl. Acad. Sci. USA 1992, 89, 4734–4738. [Google Scholar] [CrossRef] [Green Version]
  19. Michalak, M.; Groenendyk, J.; Szabo, E.; Gold, L.I.; Opas, M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem. J. 2009, 417, 651–666. [Google Scholar] [CrossRef]
  20. Ahluwalia, N.; Bergeron, J.J.; Wada, I.; Degen, E.; Williams, D.B. The p88 molecular chaperone is identical to the endoplasmic reticulum membrane protein, calnexin. J. Biol. Chem. 1992, 267, 10914–10918. [Google Scholar]
  21. David, V.; Hochstenbach, F.; Rajagopalan, S.; Brenner, M.B. Interaction with newly synthesized and retained proteins in the endoplasmic reticulum suggests a chaperone function for human integral membrane protein IP90 (calnexin). J. Biol. Chem. 1993, 268, 9585–9592. [Google Scholar] [CrossRef]
  22. Cala, S.E.; Ulbright, C.; Kelley, J.S.; Jones, L.R. Purification of a 90-kDa protein (Band VII) from cardiac sarcoplasmic reticu-lum. Identification as calnexin and localization of casein kinase II phosphorylation sites. J. Biol. Chem. 1993, 268, 2969–2975. [Google Scholar] [CrossRef] [PubMed]
  23. Coe, H.; Michalak, M. ERp57, a multifunctional endoplasmic reticulum resident oxidoreductase. Int. J. Biochem. Cell Biol. 2010, 42, 796–799. [Google Scholar] [CrossRef] [PubMed]
  24. Hammond, C.; Braakman, I.; Helenius, A. Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc. Natl. Acad. Sci. USA 1994, 91, 913–917. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Helenius, A. How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. Mol. Biol. Cell 1994, 5, 253–265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Kozlov, G.; Gehring, K. Calnexin cycle-structural features of the ER chaperone system. FEBS J. 2020, 287, 4322–4340. [Google Scholar] [CrossRef] [Green Version]
  27. Parodi, A.J. Protein glucosylation and its role in protein folding. Annu. Rev. Biochem. 2000, 69, 69–93. [Google Scholar] [CrossRef] [PubMed]
  28. Caramelo, J.J.; Parodi, A.J. Getting in and out from calnexin/calreticulin cycles. J. Biol. Chem. 2008, 283, 10221–10225. [Google Scholar] [CrossRef] [Green Version]
  29. Helenius, A.; Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 2004, 73, 1019–1049. [Google Scholar] [CrossRef]
  30. Lamriben, L.; Graham, J.B.; Adams, B.M.; Hebert, D.N. N-Glycan-based ER Molecular Chaperone and Protein Quality Con-trol System: The Calnexin Binding Cycle. Traffic 2016, 17, 308–326. [Google Scholar] [CrossRef] [Green Version]
  31. Hebert, D.N.; Molinari, M. In and out of the ER: Protein folding, quality control, degradation, and related human diseases. Physiol. Rev. 2007, 87, 1377–1408. [Google Scholar] [CrossRef] [PubMed]
  32. Agellon, L.B.; Michalak, M. The Endoplasmic Reticulum and the Cellular Reticular Network. Adv. Exp. Med. Biol. 2017, 981, 61–76. [Google Scholar] [CrossRef] [PubMed]
  33. Chevet, E.; Wong, H.N.; Gerber, D.; Cochet, C.; Fazel, A.; Cameron, P.H.; Gushue, J.N.; Thomas, D.Y.; Bergeron, J.J. Phos-phorylation by CK2 and MAPK enhances calnexin association with ribosomes. EMBO J. 1999, 18, 3655–3666. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Lakkaraju, A.K.; Abrami, L.; Lemmin, T.; Blaskovic, S.; Kunz, B.; Kihara, A.; Dal Peraro, M.; van der Goot, F.G. Palmitoylated calnexin is a key component of the ribosome-translocon complex. EMBO J. 2012, 31, 1823–1835. [Google Scholar] [CrossRef] [Green Version]
  35. Lynes, E.M.; Bui, M.; Yap, M.C.; Benson, M.D.; Schneider, B.; Ellgaard, L.; Berthiaume, L.G.; Simmen, T. Palmitoylated TMX and calnexin target to the mitochondria-associated membrane. EMBO J. 2012, 31, 457–470. [Google Scholar] [CrossRef] [Green Version]
  36. Wiest, D.L.; Burgess, W.H.; McKean, D.; Kearse, K.P.; Singer, A. The molecular chaperone calnexin is expressed on the sur-face of immature thymocytes in association with clonotype-independent CD3 complexes. EMBO J. 1995, 14, 3425–3433. [Google Scholar] [CrossRef]
  37. Wiest, D.L.; Bhandoola, A.; Punt, J.; Kreibich, G.; McKean, D.; Singer, A. Incomplete endoplasmic reticulum (ER) retention in immature thymocytes as revealed by surface expression of "ER-resident" molecular chaperones. Proc. Natl. Acad. Sci. USA 1997, 94, 1884–1889. [Google Scholar] [CrossRef] [Green Version]
  38. Okazaki, Y.; Ohno, H.; Takase, K.; Ochiai, T.; Saito, T. Cell surface expression of calnexin, a molecular chaperone in the endo-plasmic reticulum. J. Biol. Chem. 2000, 275, 35751–35758. [Google Scholar] [CrossRef] [Green Version]
  39. Myhill, N.; Lynes, E.M.; Nanji, J.A.; Blagoveshchenskaya, A.D.; Fei, H.; Carmine Simmen, K.; Cooper, T.J.; Thomas, G.; Sim-men, T. The subcellular distribution of calnexin is mediated by PACS-2. Mol. Biol. Cell 2008, 19, 2777–2788. [Google Scholar] [CrossRef] [Green Version]
  40. Chen, Y.; Ma, D.; Wang, X.; Fang, J.; Liu, X.; Song, J.; Li, X.; Ren, X.; Li, Q.; Li, Q.; et al. Calnexin Impairs the Antitumor Im-munity of CD4+ and CD8+ T Cells. Cancer Immunol. Res. 2019, 7, 123–135. [Google Scholar] [CrossRef] [Green Version]
  41. Kobayashi, M.; Nagashio, R.; Jiang, S.X.; Saito, K.; Tsuchiya, B.; Ryuge, S.; Katono, K.; Nakashima, H.; Fukuda, E.; Goshima, N.; et al. Calnexin is a novel sero-diagnostic marker for lung cancer. Lung Cancer 2015, 90, 342–345. [Google Scholar] [CrossRef] [PubMed]
  42. Thompson, J.D.; Gibson, T.J.; Plewniak, F.; Jeanmougin, F.; Higgins, D.G. The CLUSTAL_X windows interface: Flexible strat-egies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997, 25, 4876–4882. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Waterhouse, A.M.; Procter, J.B.; Martin, D.M.; Clamp, M.; Barton, G.J. Jalview Version 2—A multiple sequence alignment edi-tor and analysis workbench. Bioinformatics 2009, 25, 1189–1191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Rosenbaum, E.E.; Hardie, R.C.; Colley, N.J. Calnexin is essential for rhodopsin maturation, Ca2+ regulation, and photorecep-tor cell survival. Neuron 2006, 49, 229–241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Lee, W.; Lee, T.H.; Park, B.J.; Chang, J.W.; Yu, J.R.; Koo, H.S.; Park, H.; Yoo, Y.J.; Ahnn, J. Caenorhabditis elegans calnexin is N-glycosylated and required for stress response. Biochem. Biophys. Res. Commun. 2005, 338, 1018–1030. [Google Scholar] [CrossRef]
  46. Xu, K.; Tavernarakis, N.; Driscoll, M. Necrotic cell death in C. elegans requires the function of calreticulin and regulators of Ca2+ release from the endoplasmic reticulum. Neuron 2001, 31, 957–971. [Google Scholar] [CrossRef] [Green Version]
  47. Hung, I.C.; Cherng, B.W.; Hsu, W.M.; Lee, S.J. Calnexin is required for zebrafish posterior lateral line development. Int. J. Dev. Biol. 2013, 57, 427–438. [Google Scholar] [CrossRef] [Green Version]
  48. Kraus, A.; Groenendyk, J.; Bedard, K.; Baldwin, T.A.; Krause, K.-H.; Dubois-Dauphin, M.; Dyck, J.; Rosenbaum, E.E.; Korn-gut, L.; Colley, N.J.; et al. Calnexin deficiency leads to dysmyelination. J. Biol. Chem. 2010, 285, 18928–18938. [Google Scholar] [CrossRef] [Green Version]
  49. Denzel, A.; Molinari, M.; Trigueros, C.; Martin, J.E.; Velmurgan, S.; Brown, S.; Stamp, G.; Owen, M.J. Early postnatal death and motor disorders in mice congenitally deficient in calnexin expression. Mol. Cell Biol. 2002, 22, 7398–7404. [Google Scholar] [CrossRef] [Green Version]
  50. Mesaeli, N.; Nakamura, K.; Zvaritch, E.; Dickie, P.; Dziak, E.; Krause, K.H.; Opas, M.; MacLennan, D.H.; Michalak, M. Calre-ticulin is essential for cardiac development. J. Cell Biol. 1999, 144, 857–868. [Google Scholar] [CrossRef]
  51. Paskevicius, T.; Jung, J.; Pujol, M.; Eggleton, P.; Qin, W.; Robinson, A.; Gutowski, N.; Holley, J.; Smallwood, M.; Newcombe, J.; et al. The Fabp5/calnexin complex is a prerequisite for sensitization of mice to experimental autoimmune encephalomyeli-tis. FASEB J. 2020, 34, 16662–16675. [Google Scholar] [CrossRef]
  52. Apweiler, R.; Hermjakob, H.; Sharon, N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim. Biophys. Acta 1999, 1473, 4–8. [Google Scholar] [CrossRef] [PubMed]
  53. Kornfeld, R.; Kornfeld, S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 1985, 54, 631–664. [Google Scholar] [CrossRef] [PubMed]
  54. Hebert, D.N.; Foellmer, B.; Helenius, A. Glucose trimming and reglucosylation determine glycoprotein association with cal-nexin in the endoplasmic reticulum. Cell 1995, 81, 425–433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Rodan, A.R.; Simons, J.F.; Trombetta, E.S.; Helenius, A. N-linked oligosaccharides are necessary and sufficient for association of glycosylated forms of bovine RNase with calnexin and calreticulin. EMBO J. 1996, 15, 6921–6930. [Google Scholar] [CrossRef] [PubMed]
  56. Zapun, A.; Darby, N.J.; Tessier, D.C.; Michalak, M.; Bergeron, J.J.; Thomas, D.Y. Enhanced catalysis of ribonuclease B folding by the interaction of calnexin or calreticulin with ERp57. J. Biol. Chem. 1998, 273, 6009–6012. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Frickel, E.M.; Riek, R.; Jelesarov, I.; Helenius, A.; Wuthrich, K.; Ellgaard, L. TROSY-NMR reveals interaction between ERp57 and the tip of the calreticulin P-domain. Proc. Natl. Acad. Sci. USA 2002, 99, 1954–1959. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Kozlov, G.; Bastos-Aristizabal, S.; Määttänen, P.; Rosenauer, A.; Zheng, F.; Killikelly, A.; Trempe, J.F.; Thomas, D.Y.; Gehring, K. Structural basis of cyclophilin B binding by the calnexin/calreticulin P-domain. J. Biol. Chem. 2010, 285, 35551–35557. [Google Scholar] [CrossRef] [Green Version]
  59. Kozlov, G.; Muñoz-Escobar, J.; Castro, K.; Gehring, K. Mapping the ER Interactome: The P Domains of Calnexin and Calre-ticulin as Plurivalent Adapters for Foldases and Chaperones. Structure 2017, 25, 1415–1422.e1413. [Google Scholar] [CrossRef] [Green Version]
  60. Sakono, M.; Seko, A.; Takeda, Y.; Ito, Y. PDI family protein ERp29 forms 1:1 complex with lectin chaperone calreticulin. Biochem. Biophys. Res. Commun. 2014, 452, 27–31. [Google Scholar] [CrossRef]
  61. Tannous, A.; Patel, N.; Tamura, T.; Hebert, D.N. Reglucosylation by UDP-glucose:glycoprotein glucosyltransferase 1 delays glycoprotein secretion but not degradation. Mol. Biol. Cell 2015, 26, 390–405. [Google Scholar] [CrossRef] [PubMed]
  62. Plemper, R.K.; Wolf, D.H. Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem. Sci. 1999, 24, 266–270. [Google Scholar] [CrossRef] [PubMed]
  63. Cabral, C.M.; Choudhury, P.; Liu, Y.; Sifers, R.N. Processing by endoplasmic reticulum mannosidases partitions a secretion-impaired glycoprotein into distinct disposal pathways. J. Biol. Chem. 2000, 275, 25015–25022. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Hosokawa, N.; Wada, I.; Hasegawa, K.; Yorihuzi, T.; Tremblay, L.O.; Herscovics, A.; Nagata, K. A novel ER alpha-mannosidase-like protein accelerates ER-associated degradation. EMBO Rep. 2001, 2, 415–422. [Google Scholar] [CrossRef] [Green Version]
  65. Tremblay, L.O.; Herscovics, A. Cloning and expression of a specific human alpha 1,2-mannosidase that trims Man9GlcNAc2 to Man8GlcNAc2 isomer B during N-glycan biosynthesis. Glycobiology 1999, 9, 1073–1078. [Google Scholar] [CrossRef]
  66. Meusser, B.; Hirsch, C.; Jarosch, E.; Sommer, T. ERAD: The long road to destruction. Nat. Cell Biol. 2005, 7, 766–772. [Google Scholar] [CrossRef]
  67. Jakob, C.A.; Burda, P.; Roth, J.; Aebi, M. Degradation of misfolded endoplasmic reticulum glycoproteins in Saccharomyces cerevisiae is determined by a specific oligosaccharide structure. J. Cell Biol. 1998, 142, 1223–1233. [Google Scholar] [CrossRef] [Green Version]
  68. Oda, Y.; Hosokawa, N.; Wada, I.; Nagata, K. EDEM as an acceptor of terminally misfolded glycoproteins released from cal-nexin. Science 2003, 299, 1394–1397. [Google Scholar] [CrossRef] [PubMed]
  69. Molinari, M.; Calanca, V.; Galli, C.; Lucca, P.; Paganetti, P. Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle. Science 2003, 299, 1397–1400. [Google Scholar] [CrossRef]
  70. Christianson, J.C.; Ye, Y. Cleaning up in the endoplasmic reticulum: Ubiquitin in charge. Nat. Struct. Mol. Biol. 2014, 21, 325–335. [Google Scholar] [CrossRef] [PubMed]
  71. Yang, M.; Luo, S.; Wang, X.; Li, C.; Yang, J.; Zhu, X.; Xiao, L.; Sun, L. ER-Phagy: A New Regulator of ER Homeostasis. Front. Cell Dev. Biol. 2021, 9, 684526. [Google Scholar] [CrossRef] [PubMed]
  72. Forrester, A.; De Leonibus, C.; Grumati, P.; Fasana, E.; Piemontese, M.; Staiano, L.; Fregno, I.; Raimondi, A.; Marazza, A.; Bruno, G.; et al. A selective ER-phagy exerts procollagen quality control via a Calnexin-FAM134B complex. EMBO J. 2019, 38, e99847. [Google Scholar] [CrossRef]
  73. Fregno, I.; Fasana, E.; Bergmann, T.J.; Raimondi, A.; Loi, M.; Soldà, T.; Galli, C.; D’Antuono, R.; Morone, D.; Danieli, A.; et al. ER-to-lysosome-associated degradation of proteasome-resistant ATZ polymers occurs via receptor-mediated vesicular transport. EMBO J. 2018, 37, e99259. [Google Scholar] [CrossRef] [PubMed]
  74. Diedrich, G.; Bangia, N.; Pan, M.; Cresswell, P. A role for calnexin in the assembly of the MHC class I loading complex in the endoplasmic reticulum. J. Immunol. 2001, 166, 1703–1709. [Google Scholar] [CrossRef] [Green Version]
  75. Jackson, M.R.; Cohen-Doyle, M.F.; Peterson, P.A.; Williams, D.B. Regulation of MHC class I transport by the molecular chap-erone, calnexin (p88, IP90). Science 1994, 263, 384–387. [Google Scholar] [CrossRef] [PubMed]
  76. Suh, W.K.; Mitchell, E.K.; Yang, Y.; Peterson, P.A.; Waneck, G.L.; Williams, D.B. MHC class I molecules form ternary com-plexes with calnexin and TAP and undergo peptide-regulated interaction with TAP via their extracellular domains. J. Exp. Med. 1996, 184, 337–348. [Google Scholar] [CrossRef] [Green Version]
  77. Zhang, Q.; Tector, M.; Salter, R.D. Calnexin recognizes carbohydrate and protein determinants of class I major histocompati-bility complex molecules. J. Biol. Chem. 1995, 270, 3944–3948. [Google Scholar] [CrossRef] [Green Version]
  78. Vassilakos, A.; Cohen-Doyle, M.F.; Peterson, P.A.; Jackson, M.R.; Williams, D.B. The molecular chaperone calnexin facilitates folding and assembly of class I histocompatibility molecules. EMBO J. 1996, 15, 1495–1506. [Google Scholar] [CrossRef]
  79. Prasad, S.A.; Yewdell, J.W.; Porgador, A.; Sadasivan, B.; Cresswell, P.; Bennink, J.R. Calnexin expression does not enhance the generation of MHC class I-peptide complexes. Eur. J. Immunol. 1998, 28, 907–913. [Google Scholar] [CrossRef]
  80. Sadasivan, B.K.; Cariappa, A.; Waneck, G.L.; Cresswell, P. Assembly, peptide loading, and transport of MHC class I mole-cules in a calnexin-negative cell line. Cold Spring Harb. Symp. Quant. Biol. 1995, 60, 267–275. [Google Scholar] [CrossRef]
  81. Anderson, K.S.; Cresswell, P. A role for calnexin (IP90) in the assembly of class II MHC molecules. EMBO J. 1994, 13, 675–682. [Google Scholar] [CrossRef] [PubMed]
  82. Kearse, K.P.; Williams, D.B.; Singer, A. Persistence of glucose residues on core oligosaccharides prevents association of TCR alpha and TCR beta proteins with calnexin and results specifically in accelerated degradation of nascent TCR alpha proteins within the endoplasmic reticulum. EMBO J. 1994, 13, 3678–3686. [Google Scholar] [CrossRef]
  83. Van Leeuwen, J.E.; Kearse, K.P. Calnexin associates exclusively with individual CD3 delta and T cell antigen receptor (TCR) alpha proteins containing incompletely trimmed glycans that are not assembled into multisubunit TCR complexes. J. Biol. Chem. 1996, 271, 9660–9665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Gardner, T.G.; Franklin, R.A.; Robinson, P.J.; Pederson, N.E.; Howe, C.; Kearse, K.P. T cell receptor assembly and expression in the absence of calnexin. Arch. Biochem. Biophys. 2000, 378, 182–189. [Google Scholar] [CrossRef]
  85. Van Leeuwen, J.E.; Kearse, K.P. The related molecular chaperones calnexin and calreticulin differentially associate with nas-cent T cell antigen receptor proteins within the endoplasmic reticulum. J. Biol. Chem. 1996, 271, 25345–25349. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Grupp, S.A.; Mitchell, R.N.; Schreiber, K.L.; McKean, D.J.; Abbas, A.K. Molecular mechanisms that control expression of the B lymphocyte antigen receptor complex. J. Exp. Med. 1995, 181, 161–168. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Wu, Y.; Pun, C.; Hozumi, N. Roles of calnexin and Ig-alpha beta interactions with membrane Igs in the surface expression of the B cell antigen receptor of the IgM and IgD classes. J. Immunol. 1997, 158, 2762–2770. [Google Scholar] [CrossRef]
  88. Foy, S.P.; Matsuuchi, L. Association of B lymphocyte antigen receptor polypeptides with multiple chaperone proteins. Immunol. Lett. 2001, 78, 149–160. [Google Scholar] [CrossRef]
  89. Tjoelker, L.W.; Seyfried, C.E.; Eddy, R.L., Jr.; Byers, M.G.; Shows, T.B.; Calderon, J.; Schreiber, R.B.; Gray, P.W. Human, mouse, and rat calnexin cDNA cloning: Identification of potential calcium binding motifs and gene localization to human chromosome 5. Biochemistry 1994, 33, 3229–3236. [Google Scholar] [CrossRef]
  90. Oliver, J.D.; Roderick, H.L.; Llewellyn, D.H.; High, S. ERp57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin. Mol. Biol. Cell 1999, 10, 2573–2582. [Google Scholar] [CrossRef] [Green Version]
  91. Ho, S.C.; Rajagopalan, S.; Chaudhuri, S.; Shieh, C.C.; Brenner, M.B.; Pillai, S. Membrane anchoring of calnexin facilitates its interaction with its targets. Mol. Immunol. 1999, 36, 1–12. [Google Scholar] [CrossRef] [PubMed]
  92. Dowal, L.; Yang, W.; Freeman, M.R.; Steen, H.; Flaumenhaft, R. Proteomic analysis of palmitoylated platelet proteins. Blood 2011, 118, e62–e73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Kang, R.; Wan, J.; Arstikaitis, P.; Takahashi, H.; Huang, K.; Bailey, A.O.; Thompson, J.X.; Roth, A.F.; Drisdel, R.C.; Mastro, R.; et al. Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 2008, 456, 904–909. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Yount, J.S.; Moltedo, B.; Yang, Y.Y.; Charron, G.; Moran, T.M.; López, C.B.; Hang, H.C. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat. Chem. Biol. 2010, 6, 610–614. [Google Scholar] [CrossRef]
  95. Cameron, P.H.; Chevet, E.; Pluquet, O.; Thomas, D.Y.; Bergeron, J.J. Calnexin phosphorylation attenuates the release of par-tially misfolded alpha1-antitrypsin to the secretory pathway. J. Biol. Chem. 2009, 284, 34570–34579. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Lee, D.; Kraus, A.; Prins, D.; Groenendyk, J.; Aubry, I.; Liu, W.-X.; Li, H.-D.; Julien, O.; Touret, N.; Sykes, B.D.; et al. UBC9-dependent association between calnexin and protein tyrosine phosphatase 1B (PTP1B) at the endoplasmic reticulum. J. Biol. Chem. 2015, 290, 5725–5738. [Google Scholar] [CrossRef] [Green Version]
  97. Wong, H.N.; Ward, M.A.; Bell, A.W.; Chevet, E.; Bains, S.; Blackstock, W.P.; Solari, R.; Thomas, D.Y.; Bergeron, J.J. Conserved in vivo phosphorylation of calnexin at casein kinase II sites as well as a protein kinase C/proline-directed kinase site. J. Biol. Chem. 1998, 273, 17227–17235. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  98. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Zidek, A.; Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021, 596, 583–589. [Google Scholar] [CrossRef]
  99. Schrag, J.D.; Bergeron, J.J.; Li, Y.; Borisova, S.; Hahn, M.; Thomas, D.Y.; Cygler, M. The Structure of calnexin, an ER chaper-one involved in quality control of protein folding. Mol. Cell 2001, 8, 633–644. [Google Scholar] [CrossRef]
  100. Trombetta, E.S.; Helenius, A. Lectins as chaperones in glycoprotein folding. Curr. Opin. Struct. Biol. 1998, 8, 587–592. [Google Scholar] [CrossRef]
  101. Baksh, S.; Michalak, M. Expression of calreticulin in Escherichia coli and identification of its Ca2+ binding domains. J. Biol. Chem. 1991, 266, 21458–21465. [Google Scholar] [CrossRef] [PubMed]
  102. Ou, W.J.; Bergeron, J.J.; Li, Y.; Kang, C.Y.; Thomas, D.Y. Conformational changes induced in the endoplasmic reticulum lu-minal domain of calnexin by Mg-ATP and Ca2+. J. Biol. Chem. 1995, 270, 18051–18059. [Google Scholar] [CrossRef] [Green Version]
  103. Ihara, Y.; Cohen-Doyle, M.F.; Saito, Y.; Williams, D.B. Calnexin discriminates between protein conformational states and functions as a molecular chaperone in vitro. Mol. Cell 1999, 4, 331–341. [Google Scholar] [CrossRef] [PubMed]
  104. Leach, M.R.; Cohen-Doyle, M.F.; Thomas, D.Y.; Williams, D.B. Localization of the lectin, ERp57 binding, and polypeptide binding sites of calnexin and calreticulin. J. Biol. Chem. 2002, 277, 29686–29697. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Rajagopalan, S.; Xu, Y.; Brenner, M.B. Retention of unassembled components of integral membrane proteins by calnexin. Science 1994, 263, 387–390. [Google Scholar] [CrossRef]
  106. Dallavilla, T.; Abrami, L.; Sandoz, P.A.; Savoglidis, G.; Hatzimanikatis, V.; van der Goot, F.G. Model-Driven Understanding of Palmitoylation Dynamics: Regulated Acylation of the Endoplasmic Reticulum Chaperone Calnexin. PLoS Comput. Biol. 2016, 12, e1004774. [Google Scholar] [CrossRef]
  107. Hayashi, T.; Su, T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007, 131, 596–610. [Google Scholar] [CrossRef] [Green Version]
  108. De Brito, O.M.; Scorrano, L. An intimate liaison: Spatial organization of the endoplasmic reticulum-mitochondria relation-ship. EMBO J. 2010, 29, 2715–2723. [Google Scholar] [CrossRef] [Green Version]
  109. Ou, W.J.; Thomas, D.Y.; Bell, A.W.; Bergeron, J.J. Casein kinase II phosphorylation of signal sequence receptor alpha and the associated membrane chaperone calnexin. J. Biol. Chem. 1992, 267, 23789–23796. [Google Scholar] [CrossRef]
  110. Nguyên, D.T.; Kebache, S.; Fazel, A.; Wong, H.N.; Jenna, S.; Emadali, A.; Lee, E.H.; Bergeron, J.J.; Kaufman, R.J.; Larose, L.; et al. Nck-dependent activation of extracellular signal-regulated kinase-1 and regulation of cell survival during endoplasmic reticulum stress. Mol. Biol. Cell 2004, 15, 4248–4260. [Google Scholar] [CrossRef]
  111. Li, C.; Li, L.; Yang, M.; Zeng, L.; Sun, L. PACS-2: A key regulator of mitochondria-associated membranes (MAMs). Pharmacol. Res. 2020, 160, 105080. [Google Scholar] [CrossRef] [PubMed]
  112. Bollo, M.; Paredes, R.M.; Holstein, D.; Zheleznova, N.; Camacho, P.; Lechleiter, J.D. Calcineurin interacts with PERK and dephosphorylates calnexin to relieve ER stress in mammals and frogs. PLoS ONE 2010, 5, e11925. [Google Scholar] [CrossRef] [Green Version]
  113. Geiss-Friedlander, R.; Melchior, F. Concepts in sumoylation: A decade on. Nat. Rev. Mol. Cell Biol. 2007, 8, 947–956. [Google Scholar] [CrossRef] [PubMed]
  114. Feldhammer, M.; Uetani, N.; Miranda-Saavedra, D.; Tremblay, M.L. PTP1B: A simple enzyme for a complex world. Crit. Rev. Biochem. Mol. Biol. 2013, 48, 430–445. [Google Scholar] [CrossRef]
  115. Dudek, E.; Millott, R.; Liu, W.X.; Beauchamp, E.; Berthiaume, L.G.; Michalak, M. N-Myristoyltransferase 1 interacts with cal-nexin at the endoplasmic reticulum. Biochem. Biophys. Res. Commun. 2015, 468, 889–893. [Google Scholar] [CrossRef] [PubMed]
  116. Hunegnaw, R.; Vassylyeva, M.; Dubrovsky, L.; Pushkarsky, T.; Sviridov, D.; Anashkina, A.A.; Üren, A.; Brichacek, B.; Vassylyev, D.G.; Adzhubei, A.A.; et al. Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule In-hibitors Reversing HIV-Induced Lipid Accumulation. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 1758–1771. [Google Scholar] [CrossRef] [Green Version]
  117. Myrum, C.; Soulé, J.; Bittins, M.; Cavagnini, K.; Goff, K.; Ziemek, S.K.; Eriksen, M.S.; Patil, S.; Szum, A.; Nair, R.R.; et al. Arc Interacts with the Integral Endoplasmic Reticulum Protein, Calnexin. Front. Cell Neurosci. 2017, 11, 294. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  118. Jung, J.; Wang, J.; Groenendyk, J.; Lee, D.; Michalak, M.; Agellon, L.B. Fatty acid binding protein (Fabp) 5 interacts with the calnexin cytoplasmic domain at the endoplasmic reticulum. Biochem. Biophys. Res. Commun. 2017, 493, 202–206. [Google Scholar] [CrossRef]
  119. Jennelle, L.; Hunegnaw, R.; Dubrovsky, L.; Pushkarsky, T.; Fitzgerald, M.L.; Sviridov, D.; Popratiloff, A.; Brichacek, B.; Buk-rinsky, M. HIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin. J. Biol. Chem. 2014, 289, 28870–28884. [Google Scholar] [CrossRef] [Green Version]
  120. Waheed, A.A.; Freed, E.O. Lipids and membrane microdomains in HIV-1 replication. Virus Res. 2009, 143, 162–176. [Google Scholar] [CrossRef] [Green Version]
  121. Jung, J.; Eggleton, P.; Robinson, A.; Wang, J.; Gutowski, N.; Holley, J.; Newcombe, J.; Dudek, E.; Paul, A.M.; Zochodne, D.; et al. Calnexin is necessary for T cell transmigration into the central nervous system. JCI Insight 2018, 3, 98410. [Google Scholar] [CrossRef] [PubMed]
  122. Rao, E.; Singh, P.; Li, Y.; Zhang, Y.; Chi, Y.I.; Suttles, J.; Li, B. Targeting epidermal fatty acid binding protein for treatment of experimental autoimmune encephalomyelitis. BMC Immunol. 2015, 16, 28. [Google Scholar] [CrossRef] [PubMed]
Cells 12 00403 g001 550
Figure 1. Amino acid sequence alignment of calnexin from different species. The default Clustal X color scheme was used for similar/identical amino acid residues [42]: blue for hydrophobic, red for positively charged, magenta for negatively charged, green for polar, cyan for aromatic, pink for cysteine, orange for glycine, yellow for proline and no color for amino acid residues that are not conserved. Dashes represent gaps in the amino acid sequence. The N-terminal signal sequence, intraluminal domain, transmembrane domain and C-terminal domain are indicated based on human calnexin protein topology. The numbering of amino acid residues referred to in the figure as well as the text corresponds to the mature human calnexin protein. Alignment was performed using Multiple Alignment using Fast Fourier Transform (MAFFT) high speed multiple sequence alignment program (https://toolkit.tuebingen.mpg.de/tools/mafft; accessed 31 August 2022). Jalview [43] was used to visualize amino acid alignment. Additional calnexin sequences from different species are shown in Supplementary Figure S1.
Figure 1. Amino acid sequence alignment of calnexin from different species. The default Clustal X color scheme was used for similar/identical amino acid residues [42]: blue for hydrophobic, red for positively charged, magenta for negatively charged, green for polar, cyan for aromatic, pink for cysteine, orange for glycine, yellow for proline and no color for amino acid residues that are not conserved. Dashes represent gaps in the amino acid sequence. The N-terminal signal sequence, intraluminal domain, transmembrane domain and C-terminal domain are indicated based on human calnexin protein topology. The numbering of amino acid residues referred to in the figure as well as the text corresponds to the mature human calnexin protein. Alignment was performed using Multiple Alignment using Fast Fourier Transform (MAFFT) high speed multiple sequence alignment program (https://toolkit.tuebingen.mpg.de/tools/mafft; accessed 31 August 2022). Jalview [43] was used to visualize amino acid alignment. Additional calnexin sequences from different species are shown in Supplementary Figure S1.
Cells 12 00403 g001
Cells 12 00403 g002 550
Figure 2. Schematic linear sequence of the calnexin gene and its encoded protein. The human calnexin gene is located on a forward strand of distal end of the long arm of chromosome 5 and is comprised of 15 exons (of which 14 are protein-coding exons) transcribed to a mature transcript of 4915 bp that is translated into a 592 amino acid residue polypeptide. Linear schematic representation of the calnexin protein and the corresponding exons encoding the specific protein domains of calnexin. The white boxes in the gene schematic diagram correspond to the untranslated regions of the first and last exons. The calnexin protein schematic diagram shows the signal peptide (red), the luminal domain (green for the N-domain and blue for the P-domain), the transmembrane domain (TM, yellow) and the cytosolic C-terminal domain (orange). The hatched box represents a portion of the ER membrane. Four repeats of Motif 1 and four repeats of Motif 2 are labelled as “11112222” and depict the proline-rich amino acid sequence repeats in the P-domain. The ER retention signal (RKPRRE) is shown as the most distal C-terminal amino acid sequence.
Figure 2. Schematic linear sequence of the calnexin gene and its encoded protein. The human calnexin gene is located on a forward strand of distal end of the long arm of chromosome 5 and is comprised of 15 exons (of which 14 are protein-coding exons) transcribed to a mature transcript of 4915 bp that is translated into a 592 amino acid residue polypeptide. Linear schematic representation of the calnexin protein and the corresponding exons encoding the specific protein domains of calnexin. The white boxes in the gene schematic diagram correspond to the untranslated regions of the first and last exons. The calnexin protein schematic diagram shows the signal peptide (red), the luminal domain (green for the N-domain and blue for the P-domain), the transmembrane domain (TM, yellow) and the cytosolic C-terminal domain (orange). The hatched box represents a portion of the ER membrane. Four repeats of Motif 1 and four repeats of Motif 2 are labelled as “11112222” and depict the proline-rich amino acid sequence repeats in the P-domain. The ER retention signal (RKPRRE) is shown as the most distal C-terminal amino acid sequence.
Cells 12 00403 g002
Cells 12 00403 g003 550
Figure 3. Schematic representation of full-length membrane-embedded calnexin. Calnexin (Protein Data Bank DOI: 10.2210/pdb1JHN/pdb) has three domains: luminal domain (comprised of N and P subdomains), transmembrane domain and C-terminal domain (no experimental structural information available). The yellow circle depicts a bound Ca2+ ion. The numbering of amino acid residues in the C-terminal domain is relative to the mature N-terminus. The transmembrane domain was modelled based on molecular dynamics simulation performed by Lakkaraju et al. [34] and shows that Pro494 introduces a kink in the helix located approximately at the midpoint of the domain. The C-terminal domain was modelled using AlphaFold [98]. The calnexin C-terminal domain undergoes distinct post-translational modifications including palmitoylation at Cys482 and Cys483 [35] (shown in blue); sumoylation at Lys505 [96] (shown in green); and phosphorylation at Ser534, Ser544 and Ser563 [97] (shown in red); Asp539 proteolytic cleavage site (shown in black). Known and potential sites of post-translational modifications in the calnexin C-terminal domains of various species are shown in Supplementary Figure S1.
Figure 3. Schematic representation of full-length membrane-embedded calnexin. Calnexin (Protein Data Bank DOI: 10.2210/pdb1JHN/pdb) has three domains: luminal domain (comprised of N and P subdomains), transmembrane domain and C-terminal domain (no experimental structural information available). The yellow circle depicts a bound Ca2+ ion. The numbering of amino acid residues in the C-terminal domain is relative to the mature N-terminus. The transmembrane domain was modelled based on molecular dynamics simulation performed by Lakkaraju et al. [34] and shows that Pro494 introduces a kink in the helix located approximately at the midpoint of the domain. The C-terminal domain was modelled using AlphaFold [98]. The calnexin C-terminal domain undergoes distinct post-translational modifications including palmitoylation at Cys482 and Cys483 [35] (shown in blue); sumoylation at Lys505 [96] (shown in green); and phosphorylation at Ser534, Ser544 and Ser563 [97] (shown in red); Asp539 proteolytic cleavage site (shown in black). Known and potential sites of post-translational modifications in the calnexin C-terminal domains of various species are shown in Supplementary Figure S1.
Cells 12 00403 g003
Cells 12 00403 g004 550
Figure 4. Crystal structure of the calnexin luminal domain and its characteristics. (A) Crystal structure of the calnexin intraluminal domain. The globular N-globular domain is shown in green while the P-domain is depicted in yellow. (B) Calnexin putative Ca2+-binding site, showing a Ca2+ ion (yellow circle) coordinated by Asp416, Asp97, Ser54 and potentially Lys98. (C) Calnexin carbohydrate binding site, showing the sidechains of Tyr144, Lys146, Tyr165, Glu196, Glu405 and Met168 involved in the binding of carbohydrate moieties.
Figure 4. Crystal structure of the calnexin luminal domain and its characteristics. (A) Crystal structure of the calnexin intraluminal domain. The globular N-globular domain is shown in green while the P-domain is depicted in yellow. (B) Calnexin putative Ca2+-binding site, showing a Ca2+ ion (yellow circle) coordinated by Asp416, Asp97, Ser54 and potentially Lys98. (C) Calnexin carbohydrate binding site, showing the sidechains of Tyr144, Lys146, Tyr165, Glu196, Glu405 and Met168 involved in the binding of carbohydrate moieties.
Cells 12 00403 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Paskevicius, T.; Farraj, R.A.; Michalak, M.; Agellon, L.B. Calnexin, More Than Just a Molecular Chaperone. Cells 2023, 12, 403. https://doi.org/10.3390/cells12030403

AMA Style

Paskevicius T, Farraj RA, Michalak M, Agellon LB. Calnexin, More Than Just a Molecular Chaperone. Cells. 2023; 12(3):403. https://doi.org/10.3390/cells12030403

Chicago/Turabian Style

Paskevicius, Tautvydas, Rabih Abou Farraj, Marek Michalak, and Luis B. Agellon. 2023. "Calnexin, More Than Just a Molecular Chaperone" Cells 12, no. 3: 403. https://doi.org/10.3390/cells12030403

APA Style

Paskevicius, T., Farraj, R. A., Michalak, M., & Agellon, L. B. (2023). Calnexin, More Than Just a Molecular Chaperone. Cells, 12(3), 403. https://doi.org/10.3390/cells12030403

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop